Replies to post #2868 on GTC Biotherapeutics (fka GTCB)

[Spice is nice]

That is one way to look at it.

Another way is this is one more collaboration supporting an admission by GTC that it cares far more about their baby than their corporate health.

http://biz.yahoo.com/bw/070302/20070302005629.html?.v=1

I see no terms there. No terms mean no revenues of substance. No revenues of substance means the IP is being diluted almost as fast as the stock.

Another poster of this board revealed how GTC actually loses money providing a similar service for Merrimack, so the question "can GTC and its shareholders actually afford these developmental contracts" is a considerable one.

[wjlknew]

The PharmaThene agreement may be a bigger deal than it appears on the surface.

PharmaThene is in the process of going public through an acquisition by Healthcare Acquisition Corporation (Amex: HAQ) ... scheduled to close this summer. The following is a power point presentation by HAQ for prospective investors, but it makes interesting reading as to what is forecast in revenues for Protexia.

http://google.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4897326&Type=HTML